-
HSD17B13 Inhibitors and/or Degraders
Publication number: 20240238425
Abstract: Described herein are 3-fluoro-4-hydroxybenzamide-containing inhibitors and/or degraders, and pharmaceutical compositions containing 3-fluoro-hydroxybenzamide-containing inhibitors and/or degraders. In some embodiments, the 3-fluoro-4-hydroxybenzamide-containing compounds of the disclosure can be used to treat a condition, for example, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Type: Application
Filed: December 15, 2023
Publication date: July 18, 2024
Applicant: Pfizer Inc.
Inventors: Jan Antoinette Cusi Romero Adams, Yotam Ashkenazi, Matthew Frank Brown, Jason Kenneth Dutra, Michelle Renee Garnsey, Xinjun Hou, Jisun Lee, Yajing Lian, Deane Milford Nason, II, Steven Victor O'Neil, Amanda Brooke Pecora, Alistair Dean Richardson, Matthew Forrest Sammons, Yang Wang, Ann Sorrentino Wright, Jun Xiao, Lei Zhang, Liying Zhang
-
Methods of treating or reducing the risk of cardiovascular events and related diseases using SGLT-2 inhibitors
Patent number: 12036203
Abstract: The present invention relates to the use of certain SGLT-2 inhibitors, such as ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof, for treating, reducing the risk of and/or preventing heart failure, myocardial infarction, cardiovascular disease or cardiovascular death in animals without type 2 or type 1 diabetes mellitus, or in animals with pre-diabetes, or in animals with type 2 or type 1 diabetes mellitus or pre-diabetes.
Type: Grant
Filed: October 10, 2019
Date of Patent: July 16, 2024
Assignees: Merck Sharp & Dohme LLC, Pfizer Inc.
Inventors: Brett Lauring, Samuel S. Engel, Steven G. Terra, James M. Rusnak
-
Selectively vented biological assay devices and associated methods
Patent number: 12023671
Abstract: Selectively vented biological assay devices and methods of performing biological assays with such devices are provided herein. Disclosed devices include a selective venting element having passively tunable porosity. The methods include controlling fluid flow within the subject devices with the selective venting element.
Type: Grant
Filed: February 22, 2022
Date of Patent: July 2, 2024
Assignee: Pfizer Inc.
Inventors: Debkishore Mitra, Frank B. Myers, III, John Robert Waldeisen, Ivan Krastev Dimov
-
Devices and methods for modifying optical properties
Patent number: 12023665
Abstract: Devices and methods for modifying optical properties of biological samples or aspects thereof are provided. The subject methods include generating a reaction product with a device and reacting the reaction product to sufficiently modify an optical property to allow detection of the modified optical property.
Type: Grant
Filed: March 14, 2017
Date of Patent: July 2, 2024
Assignee: Pfizer Inc.
Inventors: Frank B. Myers, III, Debkishore Mitra, John Robert Waldeisen, Ivan Krastev Dimov
-
Manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof
Patent number: 12018031
Abstract: The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases.
Type: Grant
Filed: January 10, 2022
Date of Patent: June 25, 2024
Assignee: Pfizer Inc.
Inventors: Kapildev Kashmirilal Arora, Jacob Cole DeForest, Andrew Kevern Hills, Brian Patrick Jones, Kris Nicole Jones, Chad Arthur Lewis, Anil Mahadeo Rane
-
Immunogenic compositions and uses thereof
Patent number: 12016913
Abstract: The invention relates to immunogenic compositions comprising a capsular polysaccharide (CP) from Streptococcus agalactiae, commonly referred to as group B streptococcus (GBS), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against GBS and/or for reducing or preventing invasive GBS disease in subjects using the compositions disclosed herein. The resulting antibodies can be used to treat or prevent GBS infection via passive immunotherapy.
Type: Grant
Filed: September 14, 2021
Date of Patent: June 25, 2024
Assignee: Pfizer Inc.
Inventors: Annaliesa Sybil Anderson, Leena Shriram Bagle, Amardeep Singh Bhupender Bhalla, Miguel Angel Garcia, Lei Hu, Lakshmi Khandke, Avvari Krishna Prasad, Cindy Xudong Yang
-
Azalactam Compounds as HPK1 Inhibitors
Publication number: 20240197703
Abstract: This invention relates to compounds of general Formula I and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
Type: Application
Filed: May 8, 2023
Publication date: June 20, 2024
Applicant: PFIZER INC.
Inventors: Joyann Barber, Sujin Cho-Schultz, Matthew L. Del Bel, Rebecca Anne Gallego, Mingying He, Mehran Jalaie, Robert Steven Kania, Michele Ann McTigue, Sajiv Krishnan Nair, Anne-Marie Dechert Schmitt, Jamison Bryce Tuttle, Dahui Zhou, Ru Zhou
-
Solid forms of pyrazolo[3,4-d]pyrimidine compounds
Patent number: 12012412
Abstract: The present disclosure provides solid forms of 6-((3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one, and methods of preparing and using the same.
Type: Grant
Filed: December 16, 2022
Date of Patent: June 18, 2024
Assignee: Pfizer Inc.
Inventors: Caroline Yvette Proulx-Lafrance, John C. Amedio, Jr., Erika Volckova
-
ANTI-EDB ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
Publication number: 20240181071
Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.
Type: Application
Filed: October 23, 2023
Publication date: June 6, 2024
Applicant: Pfizer Inc.
Inventors: Andrea Therese HOOPER, Kimberly Ann MARQUETTE, Chakrapani SUBRAMANYAM, Hans-Peter GERBER, Chad Michael MAY
-
Combination of Talazoparib and an Anti-Androgen for the Treatment of DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer
Publication number: 20240180906
Abstract: This invention relates to combination therapies comprising talazoparib, or a pharmaceutically acceptable salt thereof, and an anti-androgen, or a pharmaceutically acceptable salt thereof, and associated pharmaceutical compositions, methods of treatment, and pharmaceutical uses for the treatment of metastatic castration-sensitive prostate cancer in subjects identified as having at least one DNA damage repair gene mutation.
Type: Application
Filed: March 21, 2022
Publication date: June 6, 2024
Applicants: Pfizer Inc., Astellas Pharma Inc.
Inventors: Akos Gabor Czibere, Dana Ann Kennedy
-
BENZODIAZEPINES FOR TREATING OR PREVENTING RESPIRATORY SYNCYTIAL VIRUS INFECTION
Publication number: 20240173332
Abstract: Pharmacuetical Compounds Benzodiazepine derivatives of formula (I): wherein: R1 is H or F; R2 is selected from formula (II) and formula (III) R3 is C1-C6 alkyl which is unsubstituted or substituted by CF3, or is a monocyclic 4- to 6-membered heterocyclic group containing 1 or 2 heteroatoms selected from O, N and S; R4 is H or a group selected from —X, -alk-X, —CONR6R7, C?NNR6R7, —SO2R6 and —SO2NR6R7; R4 is a group selected from —X, -alk-X, —CONR6R7, —C?NNR6R7, —SO2R6 and —SO2R6R7; X is OH or a derivative of an OH group selected from ?-amino carboxylic acid esters, carboxylic acid esters, carbonates, carbamates, ethers and phosphates: alk is C1-C6 alkylene which is unsubstituted or substituted by C3-C6 cycloalkyl; and R6 and R7 are each independently C1-C6 alkyl or C3-C6 cycloalkyl; and the pharmaceutically acceptable salts thereof are inhibitors of respiratory syncytial virus (RSV) and can therefore be used to treat or prevent an RSV infection.
Type: Application
Filed: February 24, 2022
Publication date: May 30, 2024
Applicant: Pfizer Inc.
Inventors: Matthew Barrett, Alexandre Bedernjak, George Stuart co*ckerill, James Good
-
Treatment of Breast Cancer with Amcenestrant and Palbociclib
Publication number: 20240173293
Abstract: The present disclosure provides methods of treating breast cancer with a combination of amcenestrant and palbociclib.
Type: Application
Filed: March 2, 2022
Publication date: May 30, 2024
Applicants: Sanofi, Pfizer Inc.
Inventors: Marina CELANOVIC, Gautier PAUX, Justin Thomas HOFFMAN, Sandrine ANNEHEIM, Sylvaine CARTOT-COTTON, Patrick COHEN, Alice GOSSELIN
-
Calicheamicin derivatives and antibody drug conjugates thereof
Patent number: 11993625
Abstract: The present invention is directed to novel calicheamicin derivatives useful as payloads in antibody-drug-conjugates (ADC's), and to payload-linker compounds and ADC compounds comprising the same; to pharmaceutical compositions comprising the same and to methods for using the same to treat pathological conditions such as cancer.
Type: Grant
Filed: January 10, 2018
Date of Patent: May 28, 2024
Assignee: Pfizer, Inc.
Inventors: Omar Khaled Ahmad, Stephen Paul Brown, Kenneth John Dirico, Russell Dushin, Gary Frederick Filzen, Sujiet Puthenveetil, Pavel Strop, Chakrapani Subramanyam, Lawrence N. Tumey
-
METHODS OF ADMINISTERING LONG-ACTING GROWTH HORMONE POLYPEPTIDES
Publication number: 20240166710
Abstract: The subject matter described herein is directed to methods of treating growth hormone related disorders by administering a long-acting recombinant human growth hormone. In another embodiment, a long-acting recombinant human growth hormone is administered in a composition or the combination is administered separately to treat growth deficiency in a subject previously treated with a once daily rhGH therapy.
Type: Application
Filed: March 17, 2022
Publication date: May 23, 2024
Applicants: Pfizer Inc., OPKO Biologics Ltd.
Inventors: Jóse Francisco Cara, Aleksandra Pastrak, Srinivas Rao Valluri, Michael Paul Wajnrajch
-
Antibodies specific for CD70 and their uses
Patent number: 11987634
Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.
Type: Grant
Filed: June 1, 2022
Date of Patent: May 21, 2024
Assignee: PFIZER INC.
Inventors: Siler Panowski, Tao Sai, Barbra Johnson Sasu, Surabhi Srivatsa Srinivasan, Thomas John Van Blarcom
-
ORAL SOLUTION FORMULATION
Publication number: 20240156819
Abstract: The present invention relates to an oral solution formulation or an oral powder for constitution comprising 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazirt-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, or a lactate or malate salt thereof, and a buffer system comprising lactic acid or malic acid.
Type: Application
Filed: January 23, 2024
Publication date: May 16, 2024
Applicant: Pfizer Inc.
Inventors: Ashwinkumar Jain, Weili Yu
-
Antibody Purification
Publication number: 20240158473
Abstract: Antibody compositions and methods for the purification of antibodies are provided. Purification methods provided involve the use of hydroxyapatite resin (HA) to separate an antibody of interest from one or more impurities.
Type: Application
Filed: December 21, 2023
Publication date: May 16, 2024
Applicant: PFIZER INC.
Inventors: Timothy ISKRA, Ashley Margaret SACRAMO
-
ANTI-EDB ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
Publication number: 20240156977
Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.
Type: Application
Filed: October 23, 2023
Publication date: May 16, 2024
Applicant: Pfizer Inc.
Inventors: Andrea Therese HOOPER, Kimberly Ann MARQUETTE, Chakrapani SUBRAMANYAM, Hans-Peter GERBER, Chad Michael MAY
-
Methods For Treatment of Vitiligo
Publication number: 20240156822
Abstract: Method for treating vitiligo, including active and stable non-segmental vitiligo, using compounds and analogues which inhibit certain kinases including Janus Kinase (JAK), said method comprising the step of administering to the subject in need thereof 1-[(2S,5R)-2-methyl-5-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-propen-1-one, or a pharmaceutically acceptable salt thereof.
Type: Application
Filed: March 28, 2022
Publication date: May 16, 2024
Applicant: Pfizer Inc.
Inventor: Elena Peeva
-
Fluoro-pyridinone phosphates and boronates useful as antibacterial agents
Patent number: 11981696
Abstract: The present invention is directed to a new fluoro-pyridinone hydroxamic acid phosphates and boronates of Formulae I, II and III wherein Q is selected from the group consisting of —P(O)(OH)2, —P(O)(OH)(O?M+), —P(O)(O?M+)2 and —P(O)(O?)2M2+; M+ at each occurrence is a pharmaceutically acceptable monovalent cation; and M2+ is a pharmaceutically acceptable divalent cation and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.
Type: Grant
Filed: March 14, 2019
Date of Patent: May 14, 2024
Assignee: Pfizer Inc.
Inventors: Tamim Fehme Braish, Matthew Frank Brown, Ye Che, Richard Andrew Ewin, Timothy Allan Johnson, Michael Joseph Melnick, Justin Ian Montgomery, Mark Stephen Plummer, Loren Michael Price, Usa Reilly, Daniel Uccello
